Loading...

Skip to main content

Call us on + 1 (800) 604-9114 for more information about our products

Looking for specific datasheet Manual/COA/MSDS?
Request a Manual/COA/MSDS

Interested to get a quote about our products?
Request a Quote

Testing Data

Rabbit VEGFR-1/Flt-1 (Peptide), soluble Polyclonal Antibody | anti-VEGFR-1/Flt-1 antibody

Rabbit Anti-Human VEGFR-1/Flt-1 (Peptide), soluble

Gene Names
FLT1; FLT; FLT-1; VEGFR1; VEGFR-1
Reactivity
Human esFit-1
Applications
Western Blot, Immunofluorescence, Immunohistochemistry
Purity
Protein A purified
Synonyms
VEGFR-1/Flt-1 (Peptide); soluble; Polyclonal Antibody; Rabbit Anti-Human VEGFR-1/Flt-1 (Peptide); Fms-like tyrosine kinase 1; Vascular permeability factor receptor; anti-VEGFR-1/Flt-1 antibody
Ordering
For Research Use Only!
Host
Rabbit
Reactivity
Human esFit-1
Clonality
Polyclonal
Isotype
Rabbit IgG
Purity/Purification
Protein A purified
Form/Format
Lyophilized
Sequence Length
687
Applicable Applications for anti-VEGFR-1/Flt-1 antibody
Western Blot (WB), Immunofluorescence (IF), Immunohistochemistry (IHC)
Application Notes
WB: Use at 1-5 ug/ml
IF/IHC: Use at 1-5 ug/ml (IF)

Note: Optimal dilutions should be determined by each laboratory for each application.
Immunogen
Peptide: GEHCNKKAVFSRISKFKSTR NDSTTQSNVKH.
Preparation
Produced from sera of rabbits pre-immunized with a peptide consisting of the unique C-terminal end of esFlt-1: GEHC NKKAVFSRISKFKSTRNDSTTQSNVKH
Buffer
PBS
Reconstitution
Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Preparation and Storage
The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C. Avoid repeated freeze and thaw cycles.

Testing Data

Testing Data

Testing Data #2

Testing Data #2
Related Product Information for anti-VEGFR-1/Flt-1 antibody
Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is the naturally occurring form and was cloned from total RNA of human umbilical vein endothelial cells. The recombinant mature sVEGFR-1 is a glycosylated monomeric proteinwith a mass of approximately 96kDa. The soluble receptor protein consists of the first 6 extracellular domains (Met1-His688) containing the unique 31 amino acids residues at the C-terminus.Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells.The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly, a naturally occurring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis binding VEGF with the same affinity as the full-length receptor.
References
1. Barleon et al., 1997, J Biol Chem 272:10382-8 2. Röckl et al., 1998, Exp Cell Res, 241: 161-170].

NCBI and Uniprot Product Information

NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
NCBI Official Full Name
vascular endothelial growth factor receptor 1 isoform 2
NCBI Official Synonym Full Names
fms-related tyrosine kinase 1
NCBI Official Symbol
FLT1
NCBI Official Synonym Symbols
FLT; FLT-1; VEGFR1; VEGFR-1
NCBI Protein Information
vascular endothelial growth factor receptor 1; fms-like tyrosine kinase 1; tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
UniProt Protein Name
Vascular endothelial growth factor receptor 1
UniProt Gene Name
FLT1
UniProt Synonym Gene Names
FLT; FRT; VEGFR1; VEGFR-1; FLT-1; FLT
UniProt Entry Name
VGFR1_HUMAN

NCBI Description

This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened, soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.[provided by RefSeq, May 2009]

Uniprot Description

Function: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. Ref.2 Ref.4 Ref.5 Ref.6 Ref.15 Ref.16 Ref.17 Ref.19 Ref.21 Ref.22 Ref.23 Ref.24 Ref.26 Ref.27 Ref.29 Ref.30 Ref.31 Ref.34

Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. Ref.14 Ref.15 Ref.17 Ref.22 Ref.24

Enzyme regulation: Present in an inactive conformation in the absence of bound ligand. Binding of VEGFA, VEGFB or PGF leads to dimerization and activation by autophosphorylation on tyrosine residues.

Subunit structure: Interacts with VEGFA, VEGFB and PGF. Monomer in the absence of bound VEGFA, VEGFB or PGF. Homodimer in the presence of bound VEGFA, VEGFB and PGF. Can also form a heterodimer with KDR. Interacts (when tyrosine phosphorylated) with CBL, CRK, GRB2, NCK1, PIK3R1, PLCG, PSEN1 and PTPN11. Probably interacts also with PTPRB. Interacts with GNB2L1/RACK1. Identified in a complex with CBL and CD2AP. Ref.2 Ref.3 Ref.14 Ref.15 Ref.17 Ref.18 Ref.20 Ref.22 Ref.24 Ref.25 Ref.32 Ref.33 Ref.43 Ref.45

Subcellular location: Isoform 1: Cell membrane; Single-pass type I membrane protein. Endosome. Note: Autophosphorylation promotes ubiquitination and endocytosis. Ref.2 Ref.4 Ref.5 Ref.20 Ref.25Isoform 2: Secreted Ref.2 Ref.4 Ref.5 Ref.20 Ref.25. Isoform 3: Secreted Ref.2 Ref.4 Ref.5 Ref.20 Ref.25. Isoform 4: Secreted Ref.2 Ref.4 Ref.5 Ref.20 Ref.25. Isoform 5: Cytoplasm

Potential Ref.2 Ref.4 Ref.5 Ref.20 Ref.25. Isoform 6: Cytoplasm

Potential Ref.2 Ref.4 Ref.5 Ref.20 Ref.25. Isoform 7: Cytoplasm

Potential Ref.2 Ref.4 Ref.5 Ref.20 Ref.25.

Tissue specificity: Detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC). Ref.5 Ref.6

Induction: Up-regulated in coculture of VSMC/endothelial cell (EC) or by direct exposure to VEGF of VSMC monoculture. Up-regulated from the second trimester of pregnancy to the term and in the placenta of women with preeclampsia (PE). Up-regulated in monocytes exposed to bacterial lipopolysaccharide (LPS). Ref.5 Ref.16 Ref.34

Domain: The second and third Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFA binding. Ref.42 Ref.45

Post-translational modification: N-glycosylated. Ref.3 Ref.20Ubiquitinated after VEGFA-mediated autophosphorylation, leading to proteolytic degradation. Ref.25Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-1169 is important for interaction with PLCG. Phosphorylation at Tyr-1213 is important for interaction with PIK3R1, PTPN11, GRB2, and PLCG. Phosphorylation at Tyr-1333 is important for endocytosis and for interaction with CBL, NCK1 and CRK. Is probably dephosphorylated by PTPRB. Ref.14 Ref.15 Ref.17 Ref.18 Ref.20 Ref.22 Ref.24 Ref.25 Ref.29 Ref.33

Involvement in disease: Can contribute to cancer cell survival, proliferation, migration, and invasion, and tumor angiogenesis and metastasis. May contribute to cancer pathogenesis by promoting inflammatory responses and recruitment of tumor-infiltrating macrophages.Abnormally high expression of soluble isoforms (isoform 2, isoform 3 or isoform 4)may be a cause of preeclampsia.

Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.Contains 7 Ig-like C2-type (immunoglobulin-like) domains.Contains 1 protein kinase domain.

Research Articles on VEGFR-1/Flt-1

Similar Products

Product Notes

The VEGFR-1/Flt-1 flt1 (Catalog #AAA691267) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Rabbit Anti-Human VEGFR-1/Flt-1 (Peptide), soluble reacts with Human esFit-1 and may cross-react with other species as described in the data sheet. AAA Biotech's VEGFR-1/Flt-1 (Peptide), soluble can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunofluorescence (IF), Immunohistochemistry (IHC). WB: Use at 1-5 ug/ml IF/IHC: Use at 1-5 ug/ml (IF) Note: Optimal dilutions should be determined by each laboratory for each application. Researchers should empirically determine the suitability of the VEGFR-1/Flt-1 flt1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "VEGFR-1/Flt-1 (Peptide), soluble, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.

Precautions

All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.

Disclaimer

Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.

Item has been added to Shopping Cart

If you are ready to order, navigate to Shopping Cart and get ready to checkout.

Looking for a specific manual?
Request a Manual

Request more Information

Please complete the form below and a representative will contact you as soon as possible.

Request a Manual

Please complete the form below and a representative will contact you as soon as possible.

Request a Quote

Please complete the form below and a representative will contact you as soon as possible.